One Lambda, a provider of antibody detection assays, has entered into collaboration agreement with CellTrend.

Under the agreement, CellTrend has gained rights to distribute One Lambda’s Angiotensin II Receptor (AT1R) assay to improve the quality of life for transplant patients.

The ELISA based assay is designed to screen non-HLA antibodies that form against AT1R that are involved in various neurohumoral systems and expressed on cells of several bodily organs including the heart, liver, lungs and kidneys.

One Lambda marketing director Stewart Han said, "One Lambda is delighted to have CellTrend part of their team and that the addition of the AT1R assay to the already comprehensive HLA antibody monitoring products, positions OLI at the forefront of transplant diagnostics."

OLI said it is planning to unveil the AT1R Immuno-assay in the third quarter of 2012.